» Articles » PMID: 22859939

Sirolimus Induced Phosphaturia is Not Caused by Inhibition of Renal Apical Sodium Phosphate Cotransporters

Overview
Journal PLoS One
Date 2012 Aug 4
PMID 22859939
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The vast majority of glomerular filtrated phosphate is reabsorbed in the proximal tubule. Posttransplant phosphaturia is common and aggravated by sirolimus immunosuppression. The cause of sirolimus induced phosphaturia however remains elusive. Male Wistar rats received sirolimus or vehicle for 2 or 7 days (1.5mg/kg). The urine phosphate/creatinine ratio was higher and serum phosphate was lower in sirolimus treated rats, fractional excretion of phosphate was elevated and renal tubular phosphate reabsorption was reduced suggesting a renal cause for hypophosphatemia. PTH was lower in sirolimus treated rats. FGF 23 levels were unchanged at day 2 but lower in sirolimus treated rats after 7 days. Brush border membrane vesicle phosphate uptake was not altered in sirolimus treated groups or by direct incubation with sirolimus. mRNA, protein abundance, and subcellular transporter distribution of NaPi-IIa, Pit-2 and NHE3 were not different between groups but NaPi-IIc mRNA expression was lower at day 7. Transcriptome analyses revealed candidate genes that could be involved in the phosphaturic response. Sirolimus caused a selective renal phosphate leakage, which was not mediated by NaPi-IIa or NaPi-IIc regulation or localization. We hypothesize that another mechanism such as a basolateral phosphate transporter may be responsible for the sirolimus induced phosphaturia.

Citing Articles

Rapamycin treatment induces tubular proteinuria: role of megalin-mediated protein reabsorption.

Peres R, Peruchetti D, Silva-Aguiar R, Teixeira D, Gomes C, Takiya C Front Pharmacol. 2023; 14:1194816.

PMID: 37484026 PMC: 10359992. DOI: 10.3389/fphar.2023.1194816.


[Pattern of biochemical markers of mineral and bone disorders in kidney transplant recipients: real-world data].

Vatazin A, Parshina E, Kantaria R, Stepanov V, Zulkarnaev A Probl Endokrinol (Mosk). 2023; 69(2):47-57.

PMID: 37448271 PMC: 10204791. DOI: 10.14341/probl13167.


Lack of PTEN in osteocytes increases circulating phosphate concentrations by decreasing intact fibroblast growth factor 23 levels.

Kawai M, Kinoshita S, Ozono K, Michigami T Sci Rep. 2020; 10(1):21501.

PMID: 33299044 PMC: 7726559. DOI: 10.1038/s41598-020-78692-6.


The tripartite interaction of phosphate, autophagy, and αKlotho in health maintenance.

Shi M, Maique J, Shaffer J, Davidson T, Sebti S, Fernandez A FASEB J. 2020; 34(2):3129-3150.

PMID: 31908069 PMC: 7286356. DOI: 10.1096/fj.201902127R.


Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges.

Viana S, Reis F, Alves R Oxid Med Cell Longev. 2018; 2018:3693625.

PMID: 30510618 PMC: 6231362. DOI: 10.1155/2018/3693625.


References
1.
Biber J, Stieger B, Stange G, Murer H . Isolation of renal proximal tubular brush-border membranes. Nat Protoc. 2007; 2(6):1356-9. DOI: 10.1038/nprot.2007.156. View

2.
Moorhead J, Wills M, Ahmed K, Baillod R, Varghese Z, Tatler G . Hypophosphataemic osteomalacia after cadaveric renal transplantation. Lancet. 1974; 1(7860):694-7. DOI: 10.1016/s0140-6736(74)92902-x. View

3.
Moz Y, Levi R, Lavi-Moshayoff V, Cox K, Molkentin J, Silver J . Calcineurin Abeta is central to the expression of the renal type II Na/Pi co-transporter gene and to the regulation of renal phosphate transport. J Am Soc Nephrol. 2004; 15(12):2972-80. DOI: 10.1097/01.ASN.0000144207.44469.BE. View

4.
LASSITER W, COLINDRES R . Phosphate reabsorption in the distal convoluted tubule. Adv Exp Med Biol. 1982; 151:21-32. DOI: 10.1007/978-1-4684-4259-5_3. View

5.
Reimer R, Edwards R . Organic anion transport is the primary function of the SLC17/type I phosphate transporter family. Pflugers Arch. 2003; 447(5):629-35. DOI: 10.1007/s00424-003-1087-y. View